Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-270 Monotherapy and Combined With Adebelimab in High-Risk Recurrent Solid Tumors
NCT07348042Phase 1Recruiting
- Sponsor
- Xian-Jun Yu
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGL-270 in solid tumor (3 arms), sponsored by Xian-Jun Yu. Primary endpoint: Maximum Tolerated Dose at 24 weeks. Started Sep 2025; status: recruiting.
02
Drugs
RGL-270
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07348042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348042.